Treating spinal muscular atrophy with nusinersen has adverse effects and subjective effects only


  • Nusinersen had serious adverse effects and only provided subjective improvements in some people with spinal muscular atrophy (SMA).

Why this matters

    Evidence of improvement following treatment with nusinersen for SMA in adults was subjective only and not substantiated in objective measures, indicating a possible placebo effect.

¿Quiere leer más?

Inicie sesión o regístrese para acceder a todo el contenido de Neurodiem.

¿Ya tiene una cuenta? Inicie sesión

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.